[Quality of life of patients with prostate cancer under androgen deprivation with GnRH analogues: Results of the noninterventional study TRIPTOSIX].

What Was Tested

The paper reports a study of Gonadotropin-Releasing Hormone, published as a clinical trial.

Androgen deprivation (ADT) is a palliative therapy for patients with advanced PCa, which is given over long periods and usually continued in combination with other therapies even after progression of the disease.

Predefined subgroup analyses were performed to assess the impact of demographics, anamnestic and clinical parameters on QoL.

Why It Was Studied

In Germany, data on the quality of life (QoL) of patients with advanced prostate cancer (PCa) under therapy with gonadotropin-releasing hormone (GnRH) analogues are limited.

Who Took Part

The abstract describes 608 patients taking part.

By PubMed's age tags, the people studied were middle-aged adults, older adults and people over 80, men only.

This prospective, noninterventional study at 129 centers in Germany included 608 patients with advanced PCa treated with triptorelin.

How the Study Was Run

Quality of life was assessed at baseline and after 6 and 12 months, using validated EORTC QLQ-C30 and QLQ-PR25 questionnaires.

What Was Measured

The subject headings attached to it are Androgen Antagonists, Germany, Gonadotropin-Releasing Hormone, Prostatic Neoplasms, Quality of Life and Triptorelin Pamoate.

Author keywords: Adenocarcinoma, Hormone therapy, Palliative care and Sexual dysfunction.

What This Means in Plain Language

This is a clinical trial of Gonadotropin-Releasing Hormone in 608 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2016 (Der Urologe. Ausg. A), a journal based in Germany.

More context: all human trials.